Oban BioPharma Overview
- Year Founded
-
2023
- Status
-
Private
- Latest Deal Type
-
Series A1
- Latest Deal Amount
-
$11M
- Investors
-
2
Oban BioPharma General Information
Description
Developer of an AI-assisted targeted therapeutic platform designed to develop a novel class of therapeutics for GPCRs. The company has adopted a streamlined approach based on computerized allosteric pocket mapping, coupled to a multidimensional in silico screening process using state-of-the-art tools with compound databases comprising more than a billion structures, pre-curated for drug-like chemical properties, that combine advanced computational and AI-assisted approaches for targeted therapeutic development, enabling users to get advanced systems to create an efficient path to new medicines.
Contact Information
Website
obanbiopharma.comCorporate Office
- 1 Landmark Square
- Suite 2001
- Stamford, CT 06901
- United States
Corporate Office
- 1 Landmark Square
- Suite 2001
- Stamford, CT 06901
- United States
Oban BioPharma Timeline
Oban BioPharma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Early Stage VC (Series A1) | 03-Jun-2026 | $11M | Completed | Clinical Trials - General | ||
| 2. Early Stage VC (Series A) | 10-Jul-2024 | Completed | Clinical Trials - General | |||
| 1. Seed Round | $500K | $500K | Completed | Clinical Trials - General |
Oban BioPharma Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A-1 | ||||||||
| Series A | ||||||||
| Seed | 1,025,000 | $0.000100 | $0.5 | $0.5 | 1x | $0.5 | 15.26% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Oban BioPharma Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Oban BioPharma Patents
Oban BioPharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026231721-A1 | Novel compounds, compositions and uses thereof for treatment of neuropsychiatric disorders and related conditions | Pending | 29-Apr-2025 |
Oban BioPharma Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Apple Core Holdings | Venture Capital | Minority | ||
| Connecticut Innovations | Venture Capital | Minority |
Oban BioPharma FAQs
-
When was Oban BioPharma founded?
Oban BioPharma was founded in 2023.
-
Where is Oban BioPharma headquartered?
Oban BioPharma is headquartered in Stamford, CT.
-
What industry is Oban BioPharma in?
Oban BioPharma’s primary industry is Therapeutic Devices.
-
Is Oban BioPharma a private or public company?
Oban BioPharma is a Private company.
-
What is the current valuation of Oban BioPharma?
The current valuation of Oban BioPharma is .
-
What is Oban BioPharma’s current revenue?
The current revenue for Oban BioPharma is .
-
How much funding has Oban BioPharma raised over time?
Oban BioPharma has raised $22.5M.
-
Who are Oban BioPharma’s investors?
Apple Core Holdings and Connecticut Innovations have invested in Oban BioPharma.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
